J9347
J9347 – Injection, tremelimumab-actl, 1 mg · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 2 NDCs crosswalked per 1 MG $146.894/unit ASP+6%
📋 J9347 summary
J9347 is a HCPCS Level II J-code used to bill tremelimumab-actl, 1 mg, billed per 1 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J9347: Imjudo
Code J9347
Billing unit 1 MG Payment limit $146.894/unit NDC-Crosswalk 2
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ9347
DescriptorInjection, tremelimumab-actl, 1 mg
Billing unit1 MG
Payment limit / unit$146.894
Est. ASP / unit$138.579 est.
Mapped NDCs2
Data periodQ3 2026
Last updated2026-08-20
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$146.894
Est. ASP / unit
$138.579 est.
Est. after 2% sequester
$143.956
HCPCS dosage
1 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, tremelimumab-actl, 1 mg
CoverageC — Carrier/MAC judgment
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1D
ASC payment groupYY
Action codeN — No maintenance this year
Effective date2023-07-01
Date added2023-07-01
Source: CMS HCPCS Level II code file (imported via admin).
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J9347 = 1 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J9347 WITH EST. MEDICARE PAY
2 NDCs map to J9347. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($146.894/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 00310-4505-25 | IMJUDO tremelimumab 25 mg/1.25mL INJECTION, SOLUTION | AstraZeneca | 1 VIAL in 1 CARTON (0310-4505-25) / 1.25... | 25 mg/1.25mL | 25 | $3,672.35 | — | ● Active | CMS + PDAC |
| 00310-4535-30 | IMJUDO tremelimumab 300 mg/15mL INJECTION, SOLUTION | AstraZeneca | 1 VIAL in 1 CARTON (0310-4535-30) / 15 mL... | 300 mg/15mL | 300 | $44,068.20 | — | ● Active | CMS + PDAC |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)
Period
Total Part B spend
$14.18M
Claims
489
Beneficiaries
373
Spend / beneficiary
$38,027.23
Spend / claim
$29,006.46
Trend by period
Where J9347 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #151 of 824
#146
FULPHILA Q5108
$15.02M
#147
FLUAD * 90653
$15.02M
#148
EXPAREL J0666
$15.01M
#149
ZUSDURI J9282
$14.54M
#150
BOMYNTRA* Q5158
$14.42M
#151
IMJUDO J9347
$14.18M
#152
HERCEPTIN J9355
$13.84M
#153
LEVULAN J7308
$13.55M
#154
MEMBRANE GRAFT OR WR... Q4205
$13.47M
#155
RENFLEXIS Q5104
$12.69M
#156
DOCIVYX J9172
$12.62M
Total claims — #459 of 824
#454
IMLYGIC J9325
503
#455
MICAFUNGIN(J2248)* J2248
497
#456
ADSTILADRIN J9029
497
#457
XCELL AMNIO MATRIX P... Q4280
495
#458
EPICORD 1 SQ CM** Q4187
490
#459
IMJUDO J9347
489
#460
XIPERE J3299
487
#461
IMAAVY J9256
487
#462
NEXVIAZYME J0219
481
#463
LIDOCAINE HCL IN 5%... J2002
477
#464
VINORELBINE TARTRATE J9390
477
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (2)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2026 (Q1) | $14.18M | 373 | 489 | $38,027.23 | $29,006.46 |
| 2025 (Q1-Q4) | $61.72M | 1,551 | 2,087 | $39,791.80 | $29,572.15 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$20.62M
Medicare paid
$15.98M
Submitted services
159,530
Denial rate
6.7%
Allowed / service
$138.54
Submitted charges
$51.4M
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
📊 What bills under J9347
J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.
NDC products by ingredient
NDC products by labeler
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
2 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J9347 billing FAQ
What is HCPCS code J9347?
J9347 is a HCPCS Level II J-code used to bill Injection, tremelimumab-actl, 1 mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J9347?
One unit of J9347 represents 1 MG. Report the number of units equal to the dose administered divided by 1 MG.
How many units of J9347 should I bill?
Divide the dose administered by the code's unit size (1 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J9347?
The Medicare Part B payment limit is $146.894 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $143.956 per unit. Payment limits are revised quarterly.
Which NDCs bill under J9347?
2 NDCs currently map to J9347 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J9347 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.